Skip to main content
Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.632
+0.052 (3.30%)
At close: Mar 6, 2026, 4:00 PM EST
1.600
-0.032 (-1.97%)
After-hours: Mar 6, 2026, 4:00 PM EST

Innate Pharma Revenue

Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.

Revenue (ttm)
12.64M EUR
Revenue Growth
-62.60%
P/S Ratio
10.18
Revenue / Employee
72,621 EUR
Employees
174
Market Cap
151.10M USD

Revenue Chart

* This company reports financials in EUR.

History

Fiscal Year End Revenue Change Growth
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 202069.77M-15.68M-18.35%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Sangamo Therapeutics 32.88M
Zentalis Pharmaceuticals 26.87M
Whitehawk Therapeutics 14.38M
Oramed Pharmaceuticals 2.00M
Rani Therapeutics Holdings 1.20M
Connect Biopharma Holdings 762.00K
Revenue Rankings

IPHA News

More News